TSHA | Ticker Profile - Titan Protect

TSHA

Taysha Gene Therapies, Inc.

Healthcare · Biotechnology · NMS

$5.50

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-12.99

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-97.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$12.00

+118% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 13 analysts covering this stock

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

https://www.tayshagtx.com

Country: United States Employees: 99 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.784

Good returns relative to risk taken

Kelly Fraction

0.0296

Modest edge detected — smaller position warranted

Calmar Ratio

0.506

Acceptable balance between returns and drawdown risk

Annual Return

36.9%

Historical annualised return based on price data

Max Drawdown

-72.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.23

Moves slightly more than the broader market

52W High

$7.30

25% below the year high

52W Low

$2.25

144% above the year low

Avg Volume

2,805,209

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.38

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

32.34

Heavy leverage — higher financial risk if revenues decline

Current Ratio

14.04

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

13.76

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,774.4%

Profit from core operations before interest and tax

Free Cash Flow

$-73,448,000

Negative — the business is spending more than it generates

Revenue (TTM)

$7M

Total revenue over the last 12 months

Net Income

$-129,876,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$19.00

Target Median

$12.00

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go